Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease

Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease

Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease

How can you apply the results of recent omega-3 fatty acid trials to your practice to reduce your patients’ risk of major CV events due to ASCVD?

Available credits: 0.75

Time to complete: 45 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hear about the hottest ASCVD topics presented at the International Stroke Conference! Topics range from the latest data to risk factors to watch out for across the spectrum of disease. A stroke neurologist and 2 international experts in managing ASCVD provide hard-hitting and timely information that you can put into practice today.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Mark J. Alberts, MD
    Chief of Neurology
    Hartford Hospital
    Hartford, CT 

    No relevant financial relationships reported.

    Matthew Jay Budoff, MD
    Professor of Medicine
    UCLA School of Medicine
    Torrance, CA 

    Research: Amarin
    Consulting Fees: Amarin

    Lawrence A. Leiter, MD
    Professor of Medicine and Nutritional Sciences
    University of Toronto
    Toronto, Ontario, Canada 

    Research: Kowa, Novartis
    Consulting Fees: Amarin, Amgen, AstraZeneca, Esperion, HLS, Merck, Novartis, Pfizer, Sanofi, The Medicines Company

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, has nothing to disclose.
    • Kathy Wickman, BSN, has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss recent omega-3 fatty acid outcomes trial results and their clinical implications in reducing ASCVD events
    • Translate omega-3 mechanisms with a focus on the consequences of plaque as a key clinical marker of ASCVD
    • Apply recent randomized clinical trial and evidence-based guidelines to reduce ASCVD risk
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, stroke neurologists, neurologists, critical care specialists, internists, emergency medicine physicians, and healthcare professionals with an interest in vascular stroke and ASCVD.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 45-minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free